Identification of a Class of Human Cancer Germline Genes With Transcriptional Silencing Refractory to the Hypomethylating Drug 5-Aza-2ˈ-Deoxycytidine

Oncoscience - United States
doi 10.18632/oncoscience.95
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Impact Journals, LLC

Related search

Anticancer Efficacy of Cisplatin and Trichostatin a or 5-Aza-2′-Deoxycytidine on Ovarian Cancer

British Journal of Cancer
Cancer ResearchOncology
2013English

DNA Demethylation by 5-Aza-2′-Deoxycytidine Is Imprinted, Targeted to Euchromatin, and Has Limited Transcriptional Consequences

Epigenetics and Chromatin
GeneticsMolecular Biology
2015English

Effect of Sulforaphane and 5-Aza-2’-Deoxycytidine on Melanoma Cell Growth

Medicines
2019English

Potential Role of 5-Aza-2′-Deoxycytidine Induced MAGE-A4 Expression in Immunotherapy for Anaplastic Thyroid Cancer

Surgery
Surgery
2013English

Analysis of the Methylation Status of Genes Up-Regulated by the Demethylating Agent, 5-Aza-2'-Deoxycytidine, in Esophageal Squamous Cell Carcinoma

Oncology Reports
MedicineCancer ResearchOncology
1994English

Cell Type-Specific Activation of the Cytomegalovirus Promoter by Dimethylsulfoxide and 5-Aza-2'-Deoxycytidine

International Journal of Biochemistry and Cell Biology
BiochemistryCell Biology
2008English

Resistance to 5-Aza-2'-Deoxycytidine in Genic Regions Compared to Non-Genic Repetitive Sequences

Journal of Reproduction and Development
Animal ScienceZoology
2010English

Selinexor, a First-In-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients With Myelodysplastic Syndromes Refractory to Hypomethylating Agents

Blood
BiochemistryImmunologyCell BiologyHematology
2018English

5-Aza-2′-Deoxycytidine Potentiates Antitumour Immune Response Induced by Photodynamic Therapy

European Journal of Cancer
Cancer ResearchOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy